Drug Search Results
More Filters [+]

Degarelix

Alternative Names: degarelix, firmagon, asp-3550, asp3550, asp 3550
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Degarelix injection is used to treat advanced prostate cancer (cancer that begins in the prostate [a male reproductive gland]). Degarelix injection is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. This may slow or stop the spread of prostate cancer cells that need testosterone to grow. (Sourced from: https://medlineplus.gov/druginfo/meds/a609022.html)

Mechanisms of Action: GnRH Antagonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Prostate Cancer | Oncology Unspecified

Known Adverse Events: Pain Unspecified | Erythema | Hot Flashes

Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Degarelix

Countries in Clinic: Canada, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 2: Adenocarcinoma|Prostate Cancer|Vascular Cancer

Phase 1: Bladder Cancer|Transitional Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SChLAP/IDC

P2

Not yet recruiting

Prostate Cancer

2028-12-01

Neo-Red-P

P1

Active, not recruiting

Prostate Cancer

2025-06-01

TASUC-Neo

P1

Recruiting

Transitional Cell Carcinoma|Bladder Cancer

2025-01-01

Pro00061532

P2

Active, not recruiting

Adenocarcinoma|Prostate Cancer

2024-09-30

Recent News Events